GlassScriptPhysician profile
Jamie Carden-Smith
NPI 1386127264
$3,717.32
in general payments reported to CMS, 2019-2025
25 companies · $190 in 2025
The $190 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,547 · 2022: $1,424 · 2023: $416 · 2024: $140 · 2025: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $746.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $746.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $673.04 | 2021-2022 | |
| Abbvie INC. | $545.92 | 2021-2025 | |
| Boston Scientific Corporation | $475.27 | 2021-2025 | Enroute Transcarotid Stent, Lithovue |
| Abbott Laboratories | $299.23 | 2021-2024 | Eterna |
| Amgen INC. | $232.81 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $219.68 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $188.02 | 2021-2022 | |
| Lilly USA, LLC | $180.62 | 2022-2024 | Zepbound, Jardiance, Mounjaro |
| Novo Nordisk INC | $173.55 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $148.91 | 2023 | Rexulti |
| Neurelis, INC. | $81.21 | 2023 | Valtoco |
| Medtronic, INC. | $65.64 | 2022-2023 | Kyphon Express II Kyphopak Tray |
| Lundbeck LLC | $46.52 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $44.20 | 2021 | |
| Redhill Biopharma INC. | $41.87 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $40.82 | 2023-2025 | |
| Grt US Holding, INC. | $38.60 | 2021 | |
| Allergan, INC. | $38.47 | 2021-2022 | |
| Virtus Pharmaceuticals LLC | $36.44 | 2021 | |
| Uswm, LLC | $35.52 | 2022 | |
| Hikma Pharmaceuticals USA | $33.98 | 2021 | |
| Collegium Pharmaceutical, INC. | $29.64 | 2022 | |
| Almatica Pharma LLC | $18.45 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.45 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Carden-Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.